Wed, Jan 28, 2015, 5:14 AM EST - U.S. Markets open in 4 hrs 16 mins


% | $
Quotes you view appear here for quick access.

Affymax, Inc. (AFFY) Message Board

  • this_isnt_my_real_alias this_isnt_my_real_alias Feb 24, 2013 2:52 PM Flag

    Google Epogen

    Just a snippet on Epogen...

    "What’s the problem?

    May 26, 2011 – According to a study published in the current issue of the Journal of the American Medical Association (JAMA), using the anemia drugs Epogen and Procrit (epoetin alfa) following a heart attack serves little purpose and could actually increase the risk of permanent heart damage. The new research challenges a previously held assumption by the medical community that such drugs are effective at reducing heart damage.

    The study involved 222 patients given either Epogen or Procrit or a placebo, and found that there was no difference in efficacy when it came to the prevention of heart attacks or the treatment of heart tissue damage from previous attacks. However, five participants who took the drugs experienced new heart attacks, blocked arteries, or died. None of the patients given placebos experienced any adverse side effects. The new JAMA study seems to support prior research suggesting that Epogen and Procrit may increase the risk of heart attacks, strokes, blood clots and death."

    And sales are still in the BILLIONS!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
0.1351-0.0109(-7.47%)Jan 27 3:47 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Apple Inc.
NASDAQTue, Jan 27, 2015 4:00 PM EST
Microsoft Corporation
NASDAQTue, Jan 27, 2015 4:00 PM EST
Horizon Pharma plc
NASDAQTue, Jan 27, 2015 4:00 PM EST